Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder C

Posted Apr 26 by Two Blokes

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST tria

Source: Two Blokes Trading

Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients

Posted Apr 26 by Two Blokes

Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than

Source: Two Blokes Trading

Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical ben

Posted Apr 26 by Two Blokes

Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than

Source: Two Blokes Trading

Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-ri

Posted Apr 26 by Two Blokes

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tu

Source: Two Blokes Trading

Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-ri

Posted Apr 26 by Two Blokes

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tu

Source: Two Blokes Trading

Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo\u2122 robotic-assisted surger

Posted Apr 26 by Two Blokes

Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted

Source: Two Blokes Trading

PayPal stock price analysis: buy, sell, or hold ahead of earnings?

Posted Apr 26 by Two Blokes

PayPal stock price on Tuesday, when it publishes its first-quarter financial results, will show whether its bu

Source: Two Blokes Trading

Down 20% This Year, Is Lucid Stock Finally a Buy?

Posted Apr 26 by Two Blokes

It's been a wild start to the year for Lucid Group (LCID 1.84%) investors. Founder and former CEO Peter Rawlin

Source: Two Blokes Trading

China has exempted some U.S. imports that the country would struggle to immediately source from elsewhere from its retaliatory t

Posted Apr 26 by Two Blokes

Beijing has been canvassing companies and waiving duties on American goods in sectors where it lacks alternati

Source: Two Blokes Trading

Prediction: Buying Cognex Today Will Set You Up for Life

Posted Apr 26 by Two Blokes

I'm not going to sugarcoat this: Machine vision company Cognex (CGNX 0.27%) is heading for a tough year, and t

Source: Two Blokes Trading

Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical ben

Posted Apr 26 by Two Blokes

Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than

Source: Two Blokes Trading

Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-ri

Posted Apr 26 by Two Blokes

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tu

Source: Two Blokes Trading